Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04607109
Other study ID # 2020PI166
Secondary ID
Status Completed
Phase
First received
Last updated
Start date November 2, 2020
Est. completion date July 31, 2021

Study information

Verified date March 2022
Source Central Hospital, Nancy, France
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Thanks to the evolution in knowledge and technical advances in premature newborn intensive care, the survival of very premature infants is now possible. However, prognosis remain sometimes uncertain. In 2011, the Epipage 2 study showed a significant improvement as compared with the 1997 Epipage1 study with a decrease in mortality and an increase of the survival rate without severe morbidity of 14% for preterm babies born between 25 and 29 weeks and 6% for babies born between 30 and 31 weeks. However, surviving babies without initial major deficiencies, may later show problems in terms of growth, sensory - motor and/or neuro-psychologic development. This untoward evolution lead to social and family interaction disorders and school difficulties. In this context, a perinatal care network was created for each Region in France, making it possible to take care of these vulnerable children early on and all along their development. A retrospective study will evaluate 97 pre-term babies born before 33 weeks in 2012 and who are taken care of at Nancy as part of the Lorraine regional network program "Rafael" until they are 7 years old. The objective is to evaluate objectively the neurocognitive and school abilities of these children at the age of 7. At 8 years of age, a secondary measure of outcome will be the impact of the eventual neurocognitive consequences on the quality of their family life, on the behavior of the child and the parents' feelings. This way more options to improve the way they are taken care of will be available.


Recruitment information / eligibility

Status Completed
Enrollment 238
Est. completion date July 31, 2021
Est. primary completion date June 30, 2021
Accepts healthy volunteers No
Gender All
Age group 7 Years to 8 Years
Eligibility Inclusion Criteria: - all children prematurely born between 24 and 33 completed week during 2012 - and involved in the Lorraine Perinatal Follow-up program at 7 years old Exclusion Criteria: - Children not able to respond to the EDA evaluation

Study Design


Locations

Country Name City State
France Maternity Hospital CHRU Nancy

Sponsors (1)

Lead Sponsor Collaborator
Central Hospital, Nancy, France

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary EDA score (Evaluation Des fonctions cognitives et des Apprentissages) Evaluation of learning ability by a standardized score (ranging from 15 in maths to 65 in reading, the higher score being the better) 7 years old
Secondary RAFAEL follow-up questionnaire reply of parents Questionnaire on parents feelings (with 4 levels from no impact to heavy disturbances of the family life) 8 years old
See also
  Status Clinical Trial Phase
Completed NCT04697147 - Zika and Neurodevelopment Among Infants in Grenada N/A
Completed NCT04888377 - ASPIRIN: Neurodevelopmental Follow-up Trial
Active, not recruiting NCT05504863 - RAPIDIRON Trial Follow-up Study: RAPIDIRON-KIDS Study
Completed NCT03718520 - The Influence of in Utero Cannabis Exposure on Neonatal Brain Morphology and Structural Connectivity
Completed NCT04118738 - International Cohort Study of Children Born to Women Infected With Zika Virus During Pregnancy
Recruiting NCT03476980 - Two Year Developmental Follow-up for PREMOD2 Trial (Premature Infants Receiving Milking or Delayed Cord Clamping) N/A
Completed NCT03621943 - Umbilical Cord Milking in Non-Vigorous Infants Developmental Followup (MINVIFU) N/A
Completed NCT04652063 - Osteopathic Manipulative Medicine to Reduce Developmental Delays N/A
Recruiting NCT05186155 - Analysis of Ocular and Neurodevelopmental Function for Retinopathy of Prematurity
Recruiting NCT05996211 - The Swiss Neurodevelopmental Outcome Registry for Children With CHD
Completed NCT05901623 - ASQ Scores of Transient Hypothyroxinemia of Prematurity
Enrolling by invitation NCT04529382 - Neurodevelopmental Outcome After Fetal Neonatal AlloImmune Thrombocytopenia
Recruiting NCT04347590 - Continuous Glucose Monitoring and Cerebral Oxygenation in Preterm Infants N/A
Active, not recruiting NCT03782610 - Early Prediction of Spontaneous Patent Ductus Arteriosus (PDA) Closure and PDA-Associated Outcomes